BRILAROXAZINE

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H25Cl2N3O3
Molecular Weight	450.358
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BRILAROXAZINE

Structure Search

SMILES

ClC1=C(Cl)C(=CC=C1)N2CCN(CCCCOC3=CC=C4OCC(=O)NC4=C3)CC2

InChI

InChIKey=PMKMNTBZJOXTJW-UHFFFAOYSA-N

InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)

HIDE SMILES / InChI

Molecular Formula	C22H25Cl2N3O3
Molecular Weight	450.358
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 10:38:36 GMT 2023` Edited by `admin` on `Sat Dec 16 10:38:36 GMT 2023`
Record UNII	X8L60BA01I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BRILAROXAZINE

Official Name

English

6-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-2H-BENZO(B)(1,4)OXAZIN-3(4H)-ONE

Systematic Name

English

Brilaroxazine [WHO-DD]

Common Name

English

brilaroxazine [INN]

Common Name

English

2H-1,4-BENZOXAZIN-3(4H)-ONE, 6-(4-(4-(2,3-DICHLOROPHENYL)-1-PIPERAZINYL)BUTOXY)-

Systematic Name

English

6-(4-(4-(2,3-DICHLOROPHENYL)-PIPERAZIN-1-YL)-BUTOXY)-2H-BENZO(B)(1,4)OXAZIN-3(4H)-ONE

Systematic Name

English

RP-5063

Code

English

Code System Code Type Description

CAS

1239729-06-6

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

DRUG BANK

DB09226

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

SMS_ID

100000183563

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

EPA CompTox

DTXSID001136921

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

WIKIPEDIA

RP5063

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

NCI_THESAURUS

C169817

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

FDA UNII

X8L60BA01I

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

PUBCHEM

46861612

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

CAS

2036070-48-9

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

NO STRUCTURE GIVEN

INN

10819

Created by admin on Sat Dec 16 10:38:36 GMT 2023 , Edited by admin on Sat Dec 16 10:38:36 GMT 2023

PRIMARY

Related Record Type Details


					NQI5D806LC

5-HYDROXYTRYPTAMINE RECEPTOR 2A

TARGET->PARTIAL AGONIST

Qualification:

Ki

Amount:


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					6E2Z4UWILI

5-HYDROXYTRYPTAMINE RECEPTOR 2B

TARGET -> INHIBITOR

Qualification:

Ki

Amount:


					1AG1A6ENX6

5-HYDROXYTRYPTAMINE RECEPTOR 7

TARGET -> INHIBITOR

Qualification:

Ki

Amount:


					19GBD6T9L7

D(2) DOPAMINE RECEPTOR

TARGET->PARTIAL AGONIST

Qualification:

Ki

Amount:


					RI471QC62V

D(4) DOPAMINE RECEPTOR

TARGET->PARTIAL AGONIST

Qualification:

Ki

Amount:


					W4BO00H6K6

5-HYDROXYTRYPTAMINE RECEPTOR 2C

TARGET -> INHIBITOR

Qualification:

Ki

Amount:


					I440YY0HX0

BRILAROXAZINE HYDROCHLORIDE

SALT/SOLVATE -> PARENT


					UKK18ES9TF

5-HYDROXYTRYPTAMINE RECEPTOR 1A

TARGET->PARTIAL AGONIST

Qualification:

Ki

Amount:


					G9XQ9S7T2F

D(3) DOPAMINE RECEPTOR

TARGET->PARTIAL AGONIST

Qualification:

Ki

Amount:


					8E4LAA4357

CYTOCHROME P450 2D6

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MINOR

Related Record Type Details


					X8L60BA01I

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC				DOSE PHARMACOKINETIC ROUTE OF ADMINISTRATION PHARMACOKINETIC
Tmax	PHARMACOKINETIC				ROUTE OF ADMINISTRATION PHARMACOKINETIC DOSE PHARMACOKINETIC

Cmax	PHARMACOKINETIC				ROUTE OF ADMINSTRATION PHARMACOKINETIC DOSE PHARMACOKINETIC